Frontotemporal dementia
Drug research and approvals for frontotemporal dementia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 96 studies of frontotemporal dementia are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, and FDA has 0 approved and 11 open orphan designations naming it.
- Recruiting worldwide: 96
- Trials authorized in Canada: 10
- FDA orphan approvals: 0
- EU medicines: 0
- Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence ModelsNCT07906769 · Not applicable · Istituti Clinici Scientifici Maugeri SpA · starts Oct 20, 2025
- Restoring Cervical Lymphatic Drainage in Alzheimer's DiseaseNCT07854327 · Not applicable · University of Siena · starts Jul 1, 2026
- Biofluid Research on Age-Related or Inherited NeurodegenerationNCT07798700 · Not reported · University of Pennsylvania · starts Dec 12, 2025
- Stimulating the Aging Brain Using Brain and Sensory StimulationNCT07650188 · Not applicable · Medical College of Wisconsin · starts Jun 1, 2026
- Temporal Interference Stimulation Treatment in Patients With Cognitive ImpairmentNCT07643363 · Not applicable · Tianjin Huanhu Hospital · starts Jul 1, 2026
- Retinal Hyperspectral Imaging in Neurodegenerative DiseasesNCT07545473 · Not applicable · Center for Eye Research Australia · starts Oct 11, 2021
- Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative DiseasesNCT07531732 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Apr 1, 2026
- Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic DisordersNCT07509125 · Not applicable · Universitaire Ziekenhuizen KU Leuven · starts Feb 13, 2026
- Transcranial Alternating Current Stimulation in Frontotemporal DementiaNCT07505784 · Not applicable · IRCCS Centro San Giovanni di Dio Fatebenefratelli · starts Feb 3, 2026
Phase 3 2
- MemantineGlutamate [NMDA] receptor negative allosteric modulator
- Hydromethylthionine
Phase 2 6
- OxytocinOxytocin receptor agonist
- Latozinemab
- Lithium carbonateInositol-1(or 4)-monophosphatase 1 inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- Insulin humanInsulin receptor agonist
- GalantamineAcetylcholinesterase inhibitor
Phase 1 or earlier 3
- SirolimusFK506-binding protein 1A inhibitor
- PrednisoneGlucocorticoid receptor agonist
- VerdiperstatMyeloperoxidase inhibitor
How its trials ended
260 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 39 whose ending is known, 28% met their primary endpoint, 5% missed it and 67% stopped early.
- Ongoing10540%
- Completed, result not reported9938%
- Status unknown177%
- Stopped: other or unclear166%
- Met its primary endpoint114%
- Stopped: sponsor or business decision42%
- Stopped: lack of efficacy31%
- Missed its primary endpoint21%
- Stopped: enrollment or feasibility21%
- Stopped: funding1<1%
| Mar 13, 2023 | A multicenter, open-label extension (OLE) study to evaluate the safety, pharmacodynamics, and clinical effects of WVE-004 in patients with C9ORF72-associated…WVE-004 | Wave Life Sciences Uk Ltd | Closed |
| Sep 27, 2022 | Double blind crossover trial of nabilone for agitation in frontotemporal dementia (nabilone-ftd)Nabilone | Douglas Mental Health University Institute | Closed |
| Apr 16, 2021 | A phase 1bopen-label, multicenter, dose escalationstudy to assessthe safety, tolerability and pharmacodynamic effects of a single dose of PBFT02DELIVERED into…PBFT02 / Methylprednisolone / Prednisone | Passage BIO | Ongoing |
| Jan 15, 2021 | A multicenter, randomized, double-blind, placebo-controlled, phase 1b/2a study of WVE-004 administered intrathecally to patients with C9ORF72-associated…WVE-004 | Wave Life Sciences Uk Ltd | Closed |
| Jun 21, 2019 | A phase 2, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in heterozygous carriers of…AL001 | Alector | Closed |
| Feb 13, 2019 | "a first in human phase 1 study in healthy volunteers and heterozygous carriers of a loss-of-function granulin mutation causative of frontotemporal dementia to…AL001 {recombinant anti-human sortilin (SORT1) monoclonal igg G1M17,1 [or G1M… | Alector | Pending |
| Apr 28, 2017 | A phase 2 clinical trial of intranasal oxytocin for frontotemporal dementiaOxytocin | Dr Elizabeth Finger | Ongoing |
| Aug 6, 2014 | An open-label, extension study of the effects of leuco-methylthioninium bis(hydromethanesulfonate) in subjects with Alzheimer's disease or behavioral variant…Leuco-methylthioninium bis(hydromethanesulfonate) (lmtm, TRX0237) | Taurx Therapeutics Ltd | Closed |
| Aug 26, 2013 | The impact of emotional mimicry and oxytocin on ftdOxytocin | Dr Elizabeth Finger | Ongoing |
| May 10, 2013 | A double-blind, placebo-controlled, randomized, parallel group, 12-month safety and efficacy trial of leuco-methylthioninium bis(hydromethanesulfonate) in…Leuco-methylthioninium bis(hydromethanesulfonate) (lmtm, TRX0237) | Taurx Therapeutics Ltd | Closed |
| Aug 3, 2026 | Progranulin replacement therapyTreatment of frontotemporal dementia | Denali Therapeutics Inc. | Designated |
| Nov 25, 2024 | NeflamapimodTreatment of frontotemporal dementia | EIP Pharma, LLC | Designated |
| Mar 7, 2023 | RifampinTreatment of Frontotemporal Dementia | Medilabo RFP, Inc. | Designated |
| Nov 24, 2021 | Recombinant AAV9 vector encoding the human progranulin…Treatment of frontotemporal dementia (FTD) | AviadoBio Ltd. | Designated |
| Jan 7, 2021 | Non-replicating recombinant adeno-associated virus serotype…Treatment of frontotemporal dementia | Passage Bio, Inc. | Designated |
| Sep 9, 2020 | FasudilTreatment of Frontotemporal Dementia | Woolsey Pharmaceuticals, Inc. | Designated |
| Dec 5, 2019 | Non-replicating recombinant adeno-associated virus serotype…Treatment of frontotemporal dementia | Prevail Therapeutics | Designated |
| Nov 20, 2018 | Hydromethylthionine mesylateTreatment of frontotemporal dementia | Tau Rx Therapeutics Management Ltd. | Designated |
| Nov 21, 2016 | Isoindolin-1,3-Di ThioneTreatment of Frontotemporal dementia | P2D, Inc. | Designated |
| Jul 13, 2016 | Tolfenamic acidTreatment of Frontotemporal Dementia | Nasser H. Zawia | Designated |
| Apr 6, 2016 | 1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-in…Treatment of frontotemporal dementia. | Anavex Life Sciences Corp. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA